Lead Sponsor

Daewon Pharmaceutical Co., Ltd.

Age

15 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Over 15 years old
•2. Male and Female
•3. Patients with fever over 38.0°C due to cold (acute upper respiratory tract infection)
•4. Patients with upper respiratory tract infection outbreak within 2 days and who did not received drug administration
•5. Subjects who voluntarily or legal guardian agreed with written consent

•1. Fever reducer administration Within 4 hours from the screening point
•2. Any incidence of febrile crisis from the past six months
•3. Patients with Ulcers, gastrointestinal disorders which are confirmed by endoscopy
•4. Patients with continuously administrating gastrointestinal disorder related drug
•5. Patients with severe blood damage
•6. Severe hepatic impairment (ALT, AST value more than 2 times the upper limit of the normal range)
•7. With severe renal impairment (serum creatinine value is more than 2 times the upper limit of the normal range)
•8. Patients with severe left ventricular dysfunction

Related studies

NCT06838143 · Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS), and more

NCT00001373 · Familial Mediterranean Fever (FMF), Autoinflammation, and more

NCT06579755 · Dengue Fever

NCT07158814 · Fever, Adverse Event Following Immunisation

NCT07103148 · Yellow Fever Immunization

Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection